GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
GlobeStar Therapeutics Corporation (OTCQB:GSTC) has officially upgraded from the OTC Pink tier to the OTCQB tier, maintaining the same ticker symbol. This transition, announced on October 11, 2021, reflects the company’s commitment to growth and development in the medical research sector, particularly focusing on neurodegenerative diseases. President and CEO James C. Katzaroff emphasized the importance of this move as a sign of confidence in the company's potential to deliver innovative healthcare solutions. GlobeStar aims to improve the lives of patients with chronic diseases.
- Upgrade from OTC Pink to OTCQB indicates organizational growth and commitment to stakeholders.
- Focus on neurodegenerative diseases aligns with current healthcare priorities.
- Potential to positively impact millions of patients with innovative drug development.
- None.
Company will move from the Pink tier to QB tier effective immediately while retaining the same ticker symbol.
RICHLAND, WA / ACCESSWIRE / October 11, 2021 / GlobeStar Therapeutics Corporation (OTCQB:GSTC) (www.globestarthera.com) headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease. With a mission to "help people begin their journeys to health," GlobeStar Therapeutics also brings high quality supplement products to the market.
"Our move up from the OTC Pink to OTCQB demonstrates yet again that we are moving forward as an organization and making significant progress," said James C. Katzaroff, President and CEO, GlobeStar Therapeutics Corporation. "Moving from the OTC Pink to OTCQB is a statement to our stakeholders and those we are in discussions with that GlobeStar Therapeutics is committed to our continued growth. The entire GlobeStar Therapeutics team understands the importance of this change in stock reporting."
GlobeStar's positive change in reporting is yet another vote of confidence in what we are doing and in the need for this type of drug development. GlobeStar's patented solution has the potential to change the lives of millions of patients across the globe. This life-changing neurodegenerative disease is at the forefront of the CDC and FDA's radar.
GlobeStar Therapeutics Corporation.
GlobeStar Therapeutics Corporation (OTCQB:GSTC) is a healthcare company dedicated to bringing innovative, effective, and high-quality healthcare solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, GlobeStar's team is committed to helping those suffering begin their journey back to health. More information about GlobeStar Therapeutics Corporation can be found at www.globestarthera.com.
Notice Regarding Forward Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Media Contact:
Brooke Greenwald|
Cornerstone Communications, LTD
Brooke@cornerstonepr.net
240-360-0866
SOURCE: AngioSoma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/667518/GlobeStar-Therapeutics-Corporation-Has-Been-Upgraded-to-the-QB-Tier-on-OTC-Markets
FAQ
What does the upgrade to OTCQB mean for GlobeStar Therapeutics Corporation (GSTC)?
When did GlobeStar Therapeutics upgrade to the OTCQB tier?
What is the focus of GlobeStar Therapeutics Corporation?
What does the ticker symbol GSTC refer to?
